The Chinse drug administration approved Chongqing Lummy Pharmaceutical's (SHE:300006) supplementary application for alanyl glutamine injection's two specifications, according to a Shenzhen Stock Exchange disclosure on Tuesday.
The approval covers 50 milliliters: 10 grams and 100ml:20g.
The drug is suitable for parenteral nutrition of patients who need glutamine supplementation, including those with catabolic and hypermetabolic conditions, the pharmaceutical company said.
Lummy's shares jumped more than 8% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。